Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on November 29, 2004

Stroke. 2004
Published online before print November 29, 2004, doi: 10.1161/01.STR.0000149620.74770.2e
A more recent version of this article appeared on January 1, 2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
36/1/118    most recent
01.STR.0000149620.74770.2ev1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Belayev, L.
Right arrow Articles by Bazan, N. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Belayev, L.
Right arrow Articles by Bazan, N. G.
Related Collections
Right arrow Animal models of human disease
Right arrow Acute Cerebral Infarction
Right arrow Brain Circulation and Metabolism
Right arrow Pathology of Stroke
Right arrow Neuroprotectors

Submitted on August 19, 2004
Revised on September 29, 2004
Accepted on October 5, 2004

Docosahexaenoic Acid Complexed to Albumin Elicits High-Grade Ischemic Neuroprotection

Ludmila Belayev MD; Victor L. Marcheselli PhD; Larissa Khoutorova BS; Elena B. Rodriguez de Turco PhD; Raul Busto BS; Myron D. Ginsberg MD*; and Nicolas G. Bazan MD, PhD

From the Cerebral Vascular Disease Research Center (L.B., L.K., R.B., M.D.G.), Department of Neurology, University of Miami School of Medicine, Miami, FL; and the Neuroscience Center of Excellence and Department of Ophthalmology (V.L.M., E.B.R.d.T., N.G.B.), Louisiana State University Health Sciences Center, New Orleans, La.

* To whom correspondence should be addressed. E-mail: mdginsberg{at}stroke.med.miami.edu.

Background and Purpose--High-dose human albumin therapy is strongly neuroprotective in models of brain ischemia and trauma and is currently being studied in a pilot-phase clinical stroke trial. Among its actions in ischemia, albumin induces the systemic mobilization of n-3 polyunsaturated fatty acids and may help to replenish polyunsaturated fatty acids lost from neural membranes.

Methods--We complexed 25% human albumin to docosahexaenoic acid (DHA; 22:6n-3) and compared its neuroprotective efficacy with that of native albumin in rats with 2-hour focal ischemia produced by intraluminal suture-occlusion of the middle cerebral artery.

Results--In animals treated with DHA-albumin, 0.63 g/kg, the improvement in neurobehavioral scores at 72 hours significantly exceeded that of other treatment groups, and the extent of histological protection (86% reduction in cortical infarction) was highly significant and tended to surpass the degree of cortical protection produced by native albumin at 1.25 g/kg (65%). DHA-albumin 0.63 g/kg, but not native albumin, also significantly reduced subcortical infarction and markedly diminished brain swelling. Lipidomic analysis of DHA-albumin-treated postischemic brains revealed a large accumulation of the neuroprotective DHA metabolite, 10,17S-docosatriene, in the ipsilateral hemisphere.

Conclusions--The high-grade neuroprotection afforded by the DHA-albumin complex at relatively low albumin doses is clinically advantageous in that it might reduce the likelihood of acute intravascular volume overload and congestive heart failure sometimes induced when patients with compromised cardiovascular function are treated with high-dose albumin.


Key words: albumins • ischemia • fatty acids • neuroprotection • rats




This article has been cited by other articles:


Home page
StrokeHome page
L. Belayev, L. Khoutorova, K. D. Atkins, and N. G. Bazan
Robust Docosahexaenoic Acid-Mediated Neuroprotection in a Rat Model of Transient, Focal Cerebral Ischemia
Stroke, September 1, 2009; 40(9): 3121 - 3126.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
N. G. Bazan
Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease
J. Lipid Res., April 1, 2009; 50(Supplement): S400 - S405.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
N. G. Bazan
Homeostatic Regulation of Photoreceptor Cell Integrity: Significance of the Potent Mediator Neuroprotectin D1 Biosynthesized from Docosahexaenoic Acid The Proctor Lecture
Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 4866 - 4881.
[Full Text] [PDF]


Home page
BrainHome page
W. L. Huang, V. R. King, O. E. Curran, S. C. Dyall, R. E. Ward, N. Lal, J. V. Priestley, and A. T. Michael-Titus
A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury
Brain, November 1, 2007; 130(11): 3004 - 3019.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. D. Ginsberg and M. D. Hill
Response to Letter by Parkkinen et al
Stroke, February 1, 2007; 38(2): 256 - 256.
[Full Text] [PDF]


Home page
J. Immunol.Home page
C. N. Serhan, K. Gotlinger, S. Hong, Y. Lu, J. Siegelman, T. Baer, R. Yang, S. P. Colgan, and N. A. Petasis
Anti-Inflammatory Actions of Neuroprotectin D1/Protectin D1 and Its Natural Stereoisomers: Assignments of Dihydroxy-Containing Docosatrienes
J. Immunol., February 1, 2006; 176(3): 1848 - 1859.
[Abstract] [Full Text] [PDF]